The September 9, 2025 warning-letter wave
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as September 9, 2025. Evidence tier: Official or peer-reviewed record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
FDA sent more than 50 warning letters to US and international companies that compound or manufacture semaglutide and tirzepatide, most of them dated September 9, 2025.
Targeted GLP-1 compounders and manufacturers. 15 working days to respond. Example: GLP-1 Solution 715883.
The letters targeted marketing claims that compounded products were “generic” versions of FDA-approved GLP-1 drugs or contained the “same active ingredient”, and claims of proven safety and effectiveness for weight loss. Recipients had 15 working days to respond with a corrective action plan. Unlike the December 2024 letters, these were aimed at compounders and manufacturers rather than research-labelled sellers.
Evidence tier: Official or peer-reviewed record.
Sources: FDA warning letter to GLP-1 Solution, September 9, 2025 (archived copy); Wilson Sonsini, October 1, 2025.